
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

# Journal Pre-proof




Decline of antibody titres three months after two doses of BNT162b2 in non-immunocompromised adults

Alejo Erice, David Varillas-Delgado, Cristina Caballero

PII: S1198-743X(21)00485-7

DOI: https://doi.org/10.1016/j.cmi.2021.08.023

Reference: CMI 2672

To appear in: *Clinical Microbiology and Infection*

Received Date: 19 July 2021

Revised Date: 23 August 2021

Accepted Date: 26 August 2021

Please cite this article as: Erice A, Varillas-Delgado D, Caballero C, Decline of antibody titres three months after two doses of BNT162b2 in non-immunocompromised adults, *Clinical Microbiology and Infection*, https://doi.org/10.1016/j.cmi.2021.08.023.

# Decline of antibody titres three months after two doses of BNT162b2 in non-immunocompromised adults

- ✓ The durability of the antibody response after vaccination with BNT162b2 remains to be determined.
- ✓ Anti-RBD antibodies◆ were measured◆ 1.5 and 3 months after two doses of BNT162b2.

- ✓ 230 non-immunocompromised adults (mean age: 46 years)
- ✓ 36(16%) had mild SARS-CoV-2 infection prior to vaccination.
- ✓ Median [IQR] anti-RBD titre:
  1.5 months after 2nd dose of BNT162b2:
  9,356 [5,844-16,876] AU/mL

  3 months after 2nd dose of BNT162b2:
  3,952 [2,190 - 8,561] AU/mL (p <0.001)
- ✓ Subjects with anti-RBD antibody titre >4,160 UA/mL●
  199 (86.5%) 1.5 months after 2nd dose of BNT162b2

  95 (41%) 3 months after 2nd dose of BNT162b2 (p <0.001)




- ○ The early decline of anti-RBD antibodies raises the possibility of a short-lived humoral response after BNT162b2.
- ○ Booster doses of BNT162b2 might be required to maintain high titers of anti-RBD antibodies over time.

◆ Antibodies targeted against the receptor binding domain of the spike protein of SARS-CoV-2.

◆ Chemiluminescence microparticle quantitative assay. Results expressed as AU/mL.

● Corresponds to an $ID_{50}$ of 1:250 in neutralization studies.

ASEPEYO

FRANCISCO DE VITORIA Madrid

CMI CLINICAL MICROBIOLOGY AND INFECTION

Erice A, Varillas-Delgado D, Caballero C. Clin Microbiol & Infection 2021

**Intended category:** Research note

**Title:** Decline of antibody titres three months after two doses of BNT162b2 in non-immunocompromised adults

**Authors:** Alejo Erice[1,2,*], David Varillas-Delgado[2], Cristina Caballero[3]

**Authors´ affiliations**

[1]Department of Internal Medicine, Hospital Asepeyo, Coslada (Madrid), Spain.

[2]Universidad Francisco de Vitoria, Pozuelo de Alarcón (Madrid), Spain.

[3]Clinical Diagnostic Laboratory, Hospital Asepeyo, Coslada (Madrid), Spain.

**Corresponding author**

Alejo Erice, MD

Department of Internal Medicine

Hospital Asepeyo

C/ Joaquín de Cárdenas 2

28823 Coslada (Madrid)

Spain

E-mail: aericecalvo-sotelo@asepeyo.es

Phone: +34 91 673 5011

**Length of the abstract:** 300 words

**Length of the manuscript:** 1,439 words

**Abstract**

**Objective**

To assess the antibody response in non-immunocompromised adults after two doses of BNT162b2.

**Methods**

Prospective, single-centre observational study in non-immunocompromised adults ≥ 18 years of age who received two doses of BNT162b2. The study contemplates analyses of serum samples collected 1.5, 3, 6, 9 and 12 months after the second dose of BNT162b2; results of the 1.5-and 3-months' time points are presented in this report.

Antibodies against the receptor binding domain of the S1 subunit of the spike protein of SARS-CoV-2 (anti-RBD antibodies) were measured using a commercial quantitative immunoassay. A threshold of 4,160 AU/mL (corresponding to an $ID_{50}$ of 1:250) was used as surrogate marker for serum neutralizing activity.

**Results**

Of 273 hospital workers who received two doses of BNT162b2, 260/273 (95%) agreed to participate in the study; 2/260 (0.8%) were excluded due to immunocompromised conditions. At the time of this report, 230/258 (89%) subjects [mean age: 46.0 years (SD 11.4 years); 143/230 (62%) females; 87/230 (38%) males] had completed three months of follow-up after the second dose of BNT162b2. Thirty-six (16%) subjects (36/230) had documented mild SARS-CoV-2 infection prior to receiving the first dose of BNT162b2.

Median [IQR] anti-RBD titres 1.5 months after vaccination were 9,356 [5,844 - 16,876] AU/mL; three months after vaccination, median anti-RBD titres had declined to 3,952 [2,190 - 8,561] AU/mL ($p < 0.001$). Of 199/230 (86.5%) participants who had anti-RBD

titres above 4,160 AU/mL 1.5 months after the second dose of BNT162b2, only 95/230 (41%) maintained anti-RBD titres above this level three months after vaccination ($p < 0.001$).

**Conclusions**

The decline of anti-RBD antibodies three months after the second dose of BNT162b2 is of concern because it raises the possibility of a short-lived humoral immunity after vaccination. Booster doses of BNT162b2 might be required to maintain high titers of anti-RBD antibodies over time.

## Introduction

The mRNA vaccine BNT162b2 (Pfizer-BioNtech) encoding the receptor binding domain of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein has shown 95% efficacy in preventing symptomatic infection in clinical trials [1]. In phase I/II studies, the vaccine produced robust anti-SARS-CoV-2 antibody responses in healthy adults [2,3]. However, the durability of the antibody response after vaccination with BNT162b2 remains to be determined [4,5].

## Methods

We are conducting a prospective, single-centre observational study to assess the evolution of the antibody response in non-immunocompromised hospital workers $\geq$ 18 years of age who received two doses of BNT162b2 at our institution. The study contemplates collection of serum samples 1.5, 3, 6, 9 and 12 months after the second dose of BNT162b2; analysis of results obtained 1.5 and three months after vaccination are presented in this report. At each time point, data on previous SARS-CoV-2 infection and the diagnostic method used were collected. The study was approved by the local ethics committee (approval number: 4502). All participants provided informed consent.

Antibodies against the receptor binding domain of the S1 subunit of the spike protein of SARS-CoV-2 (anti-RBD antibodies) were measured at each time point using a chemiluminescent microparticle quantitative immunoassay (Architect SARS-CoV-2 IgG II Quant, Abbott). Results were reported as concentrations (AU/mL), with a cut-off $\geq$ 50 AU/mL considered positive. For assessing the correlation between anti-RBD antibody titres and neutralizing activity, we used a threshold of 4,160 AU/mL as surrogate marker for serum neutralizing activity. This threshold corresponds to a 50% inhibitory dilution ($ID_{50}$) of 1:250 in plaque-reduction neutralization studies [6]. Antibodies targeting the SARS-CoV-2 nucleocapsid (anti-N antibodies) were measured using a

chemiluminescent microparticle immunoassay (Architect SARS-CoV-2 IgG, Abbott); results were reported as a cut-off index, with values $\geq$ 1.49 considered positive. Anti-N antibodies were only analyzed in serum samples obtained 1.5 months after the second dose of BNT162b2.

Previous SARS-CoV-2 infection was identified after review of health records by documented evidence of SARS-CoV-2 in upper respiratory tract samples by polymerase chain reaction (PCR) or antigen test, detection of SARS-COV-2 specific IgG and/or IgM (for IgM alone, concurrent symptoms were required), or a positive anti-N antibody result.

Statistical analysis was performed with SPSS, version 21.0 (IBM Corporation) for Windows. Quantitative variables are expressed as mean and standard deviation (SD) or median and interquartile range [IQR]. For comparisons between groups, chi-square tests and non-parametric Wilcoxon rank sum test were used. A two-tailed $p < 0.05$ was considered significant.

**Results**

Of 273 hospital workers who received two doses of BNT162b2 at our institution, 260/273 (95%) agreed to participate in the study; 2/260 (0.8%) were excluded due to immunocompromised conditions. At the time of this report, 230/258 (89%) subjects [mean age: 46.0 years (SD 11.4 years); 143/230 (62%) females; 87/230 (38%) males] had completed three months of follow-up after the second dose of BNT162b2. Thirty-six (16%) subjects (36/230) had documented mild SARS-CoV-2 infection prior to receiving the first dose of BNT162b2; no additional SARS-CoV-2 infections occurred in the remaining 194/230 (84%) study participants between vaccine doses or during follow-up.

Serum samples were obtained a mean of 40.1 days (SD 2.8 days) and 88.8 days (SD 2.8 days) after the second dose of BNT162b2. All participants had anti-RBD antibodies at both time points; titres were higher in men, although the differences were not statistically significant. Individuals with previous SARS-CoV-2 infection had higher anti-RBD antibody titres at both time points ($p < 0.001$). Also, 21–30-year-old participants had significantly higher anti-RBD antibody titres as compared to other age groups at both time points ($p = 0.046$ and $p = 0.023$, respectively). Results are summarized in the Table.

Three months after the second dose of BNT162b2, median anti-RBD antibodies had decreased by 58% in all study participants (from 9,356 AU/mL to 3,952 AU/mL); in individuals with previous SARS-CoV-2 infection, anti-RBD antibody titres had decreased by 51% (from 19,016 AU/mL to 9,364 AU/mL). Of 199/230 (86.5%) participants who had anti-RBD antibodies above 4,160 AU/mL 1.5 months after the second dose of BNT162b2, only 95/230 (41%) maintained anti-RBD antibody titres above this level three months after vaccination ($p < 0.001$) (Figure).

**Discussion**

This study shows a decline of anti-RBD antibodies in non-immunocompromised adults three months after the second dose of BNT162b2, regardless of previous SARS-CoV-2 infection. Until recently, a fall in antibodies following vaccination with BNT162b2 has not been described in other studies with a more limited follow-up [2,6]. Our results are consistent with those from recent reports showing a continuous decline of anti-RBD antibodies within 10 weeks after vaccination in individuals who had received two doses of BNT162b2 [7,8]. This early decay of anti-RBD antibodies is similar to that observed in patients with mild SARS-CoV-2 infection within three months after the onset of symptoms [9,10].

The significance of the decline of anti-RBD antibodies we observed is unclear because the titres of anti-RBD antibodies that are protective against SARS-CoV-2 infection have not been defined. Nevertheless, this antibody decline is of concern because it raises the possibility that protection from humoral immunity after vaccination might be short-lived. Anti-RBD antibodies are a reasonable indicator of antiviral activity, and robust correlations between anti-RBD antibodies and viral neutralizing activity have been well established, with higher anti-RBD titres correlating with higher vaccine efficacy [10-13].

Although we did not perform neutralization analyses, three months after the second dose of BNT162b2 most of our study participants had anti-RBD antibody titres that had fallen below a surrogate neutralization threshold [6]. Recently, breakthrough severe COVID-19 has been reported in fully vaccinated individuals a median of 39.5 days after the second dose of BNT162b2 [14]; their median anti-RBD antibody titre was 947.5 AU/ml, with lower values in those subjects with a poor outcome [14]. Although most of the patients were elderly (median age, 71.1 years) with comorbidities, the study suggests that a low anti-RBD antibody titre is one factor associated with breakthrough SARS-CoV-2 infection after complete vaccination with BNT162b2.

Additional follow-up is needed to determine whether the decline of anti-RBD antibodies following vaccination will continue a downward trajectory or will plateau at a lower, steady-state level. In a recent study of convalescent patients, SARS-CoV-2 antibodies declined rapidly in the first 4 months after infection; this was followed by a more gradual descent over the ensuing months with antibodies remaining detectable 11 months after infection [15]. This antibody pattern has been attributed to a transition from an early phase of secretion of serum antibodies by short-lived plasmablasts to a later phase where anti-SARS-CoV-2 antibodies are produced by a persistent population of long-lived plasma cells residing in the bone marrow [15]. It appears therefore, that humoral immunity triggered by SARS-CoV-2 infection is long-lasting;

however, it is currently unknown whether BNT162b2 produces a similar immune response. In a small study of non-infected individuals who received two doses of BNT162b2, high numbers of SARS-CoV-2 spike protein-targeting B cells were present in the germinal centers of lymph node biopsies obtained within 15 weeks of the second dose of BNT162b2 [16]. This B-cell response drives the early humoral immune response following vaccination, but its durability remains to be determined.

Anti-RBD antibodies are not the sole correlate of protection against SARS-CoV-2 infection and disease. In addition to specific antibodies and memory B cells, adaptative immunity to SARS-CoV-2 infection includes specific $CD4^+$ T cell and $CD8^+$ T cell responses. In SARS-CoV-2-infected individuals, each compartment of this complex immune response exhibits different kinetics, a marked heterogeneity among individuals, and a durability that extends beyond 6 months after onset of symptoms [17]. Although the characteristics of the cellular immune response following vaccination have not been well established, a recent study in a small group of individuals has shown that two doses of BNT162b2 induced potent SARS-CoV-2-specific $CD4^+$ T cell and $CD8^+$ T cell responses that persisted during a follow-up of 9 weeks [18].

Our study has several limitations. First, blood samples were not obtained at baseline, between the first and second doses of the vaccine or immediately after the second dose; analysis of those additional time points could have contributed to a more precise description of the kinetics of the early anti-RBD antibody response after vaccination. Second, we have not performed SARS-CoV-2 neutralization studies; therefore, we based our considerations on the correlations described in other studies between titres of binding antibodies and neutralizing capacity against SARS-CoV-2. Finally, we have not analyzed the cellular immune response following vaccination.

The significance of the decline of titres of anti-RBD antibodies against SARS-CoV-2 in terms of the long-term efficacy of BNT162b2 remains to be determined. Booster doses of BNT162b2 might be necessary to maintain high antibody titres that could prevent vaccinated individuals from becoming infected with SARS-CoV-2 and transmitting the virus to others.

**Author contributions**

AE and CC conceived, designed the study, and acquired the data. DVD analyzed the data. AE, CC and DVD interpreted the data. AE drafted the manuscript; all authors critically revised the manuscript for its intellectual content and approved the submitted version. All authors had full access to all the data in the study and agree to be accountable for all aspects of the work.

**Transparency declaration**

The authors declare that they have no conflicts of interest.

**Funding**

This work did not receive any funding from public, private or commercial agencies.

**Acknowledgements**

We are indebted to the nursing team and the laboratory technicians of the hospital for their contributions to the study. We are grateful to all study participants.

## References


1. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020; 383: 2603-15. https://doi.org/10.1056/NEJMoa203457.

2. Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, et al. COVID-19 vaccine BNT162b1 elicits human antibody and Th1 cell responses. Nature 2020; 586:594-9. https://doi.org/10.1038/s41586-020-2814-7.

3. Walsh EE, Frenck RW Jr, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. Safety and immunogenicity of two RNA-Based covid-19 vaccine candidates. N Engl J Med 2020; 383:2439-50. https://doi.org/10.1056/NEJMoa2027906.

4. Favresse J, Bayart JL, Mullier F, Dogné JM, Closset M, Douxfils J, et al. Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine BNT162b2. Clin Microbiol Infect. https//doi.org/10.1016/j.cmi.2021.05.004.

5. del Rio C, Malani P. COVID-19 in 2021—Continuing Uncertainty. JAMA 2021; 325:1389-90. doi:10.1001/jama.2021.3760.

6. Ebinger JE, Fert-Bober J, Printsev I, Wu M, Sun N, Prostko JC, et al. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat Med 2021; 27:981-4. https://doi.org/10.1038/s41591-021-01325-6.

7. Favresse J, Bayart JL, Mullier F, Elsen M, Eucher C, Van Eeckhoudt, et al. Antibody titers decline 3-month post-vaccination with BNT162b2. Emerging Microbes & Infection. https://doi.org/10.1080/22221751.2021.1953403.

8. Shrotri M, Navaratnam A, Nguyen V, Byrne T, Geismar C, Fragaszy E, et al. Spike-antibody waning after second dose of BNT162b2 or ChAdOx1. Lancet 2021; 398: 385-386. https://doi.org/10.1016/S0140-6736(21)01642-1.

9. Seow J, Graham C, Merrick B, Acors S, Pickering S, Steel KJ, et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol 2020; 5:1598-07. https://doi.org/10.1038/s41564-020-00813-8.

10. Ibarrondo FJ, Fulcher JA, Goodman-Meza D, Elliot J, Hofmann C, Hausner MA, et al. Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19. N Engl J Med 2020; 383:1085-7. https://www.nejm.org/doi/full/10.1056/nejmc2025179.

11. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med 2020; 26:1200-4. https://doi.org/10.1038/s41591-020-0965-6.

12. Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science 2020; 370:1227-30. https://doi.org/10.1126/science.abd7728.

13. Earle KA, Ambrosino DM, Fiore-Gartland A, Goldbaltt D, Gilbert PB, Siber GR, et al. Evidence for antibody as a protective correlate for COVID-19 vaccine. Vaccine 2021; 39:4423-8. https://doi.org/10.1016/j.vaccine.2021.05.063.

14. Brosh-Nissinov T, Orenbuch-Harroch E, Chowers M, Elbaz M, Nesher L, Stein M, et al. BNT162b2 vaccine breakthough: clinical characteristics of 152 fully vaccinated hospitalized COVID-129 patients in Israel. Clin Microbiol Infect. https://doi.org/10.1016/j.cmi.2021.06.036.

15. Turner JS, Kim W, Kalaidina E, Goss CW, Rauseo AM, Schmitz AJ, et al. SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans. Nature 2021; 595:421-5. https://doi.org/10.1038/s41586-021-03647-4.

16. Turner JS, O´Halloran JA, Kalaidina E, Kim W, Schmitz AJ, Zhou JQ et al. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. https://doi.org/10.1038/s41586-021-03738-2.

17. Dan JM, Mateus J, Kato Y, Hastie KM, Dawen Yu E, Faliti CE, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. https://doi.org/10.1126/science.abf4063.

18. Sahin U, Muik A, Vogler I, Derhovanessian E, Kranz LM, Vormehr M, et al. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature. https://doi.org/10.1038/S41586-021-03653-6.

**Table. Anti-RBD antibody titres after two doses BNT162b2**

| | | Anti-RBD antibody titres median [IQR] AU/mL | | | |
|---|---|---|---|---|---|
| | **N (%)** | **1.5 months after 2nd dose of BMT162b2** | **p value** | **3 months after 2nd dose of BMT162b2** | **p value** |
| **All** | 230 (100) | 9,356 [5,844 - 16,876] | - | 3,952 [2,190 - 8,561] | <0.001 |
| **Sex** | | | | | |
| Male | 143 (62) | 10,293 [6,155 - 17,292] | 0.323 | 4,292 [2,053 - 11,356] | 0.454 |
| Female | 87 (38) | 8,434 [5,751 - 16,449] | | 3,797 [2,206 - 7,711] | |
| **Previous SARS-CoV-2 infection** | | | | | |
| Yes | 36 (16) | 19,016 [7,974 - 27,885] | <0.001 | 9,364 [3,975 - 22,233] | <0.001 |
| No | 194 (84) | 8,747 [5,631 - 15,409] | | 3,724 [2,003 - 7,137] | |

| | | | | | |
|---|---|---|---|---|---|
| **Age** | | | | | |
| 20 – 30 | 29 (12.6) | 15,402 | | 5,733 | |
| | | [8,763 - 21,545] | | [3,893 - 12,891] | |
| 31 – 40 | 47 (20.4) | 7,642 | | 2,949 | |
| | | [5,683 - 13,532] | | [1,981 - 8,950] | |
| 41 – 50 | 68 (29.6) | 9,272 | 0.046 | 3,572 | 0.023 |
| | | [5,432 - 16,589] | | [1,721 - 6,771] | |
| 51 – 60 | 60 (26.1) | 9,234 | | 3,862 | |
| | | [6,251 - 17,180] | | [2,285 - 7,824] | |
| 61 – 70 | 25 (10.9) | 9,262 | | 6,176 | |
| | | [4,541 - 16,081] | | [2,193 - 14,392] | |
| 71 - 80 | 1 (0.4) | 2,165 | | 750 | |



**Fig. Anti-RBD antibody titres 1.5 and 3 months after the second doses of BNT162b2.** A $\log_{10}$ scale was used in the X axis to minimize data dispersion. In each box-and-whisker plot, the horizontal line represents the median, the top and bottom of the box the interquartile range, and the whiskers the minimum and maximum values. The horizontal line indicates an anti-RBD antibody titre of 4,160 AU/mL, which correlates with a 50% inhibitory dilution ($ID_{50}$) of 1:250 in plaque-reduction neutralization studies. Chi-square and non-parametric Wilcoxon rank sum tests were used for the following comparisons: (1) anti-RBD antibody titers in blood samples from all study participants (n = 230) measured 1.5 and 3 months after vaccination ($p < 0.001$); (2) participants with anti-RBD antibody titers that were above 4,160 AU/mL 1.5 months after vaccination (n = 199), and 3 months after vaccination (n = 95) ($p < 0.001$).